KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

Astrazeneca (AZN) Shares Outstanding (Weighted Average) (2016 - 2025)

Historic Shares Outstanding (Weighted Average) for Astrazeneca (AZN) over the last 15 years, with Q1 2025 value amounting to $1.9 million.

  • Astrazeneca's Shares Outstanding (Weighted Average) rose 3333.33% to $1.9 million in Q1 2025 from the same period last year, while for Mar 2025 it was $1.9 million, marking a year-over-year increase of 3333.33%. This contributed to the annual value of $3.2 million for FY2023, which is N/A changed from last year.
  • Astrazeneca's Shares Outstanding (Weighted Average) amounted to $1.9 million in Q1 2025, which was up 3333.33% from $3.6 million recorded in Q3 2024.
  • Astrazeneca's Shares Outstanding (Weighted Average)'s 5-year high stood at $3.6 million during Q3 2024, with a 5-year trough of $250.0 in Q1 2022.
  • Its 5-year average for Shares Outstanding (Weighted Average) is $1.7 million, with a median of $1.3 million in 2021.
  • As far as peak fluctuations go, Astrazeneca's Shares Outstanding (Weighted Average) tumbled by 9999.98% in 2021, and later soared by 46390000.0% in 2023.
  • Quarter analysis of 5 years shows Astrazeneca's Shares Outstanding (Weighted Average) stood at $1.2 million in 2021, then crashed by 99.98% to $250.0 in 2022, then soared by 1287900.0% to $3.2 million in 2023, then increased by 10.87% to $3.6 million in 2024, then tumbled by 47.34% to $1.9 million in 2025.
  • Its last three reported values are $1.9 million in Q1 2025, $3.6 million for Q3 2024, and $1.4 million during Q1 2024.